Member Info for joxer22

Thanks Bermuda. I just wonder if they could have done it some other way e.g. a share issue to the existing shareholders at that time. I know this would have caused dilution but I think that the potential cash payout of up to $85M is not the best use of capital - however, as I am going to (hopefully) benefit from it I'm not complaining!

I still cannot understand the logic of why AMYT decided to issue the various CVRs. Growth companies generally re-invest any profits or surplus funds in the business instead of paying out valuable cash in the form of dividends, which is essentially what the CVRs are. It just seems like a very inefficient way of utilizing cash in a fast growing business

The conference call was very positive and although they could not give any specific replies to questions about the PDUFA it appears that things are proceeding as expected.

Same pattern as the last few days on nasdaq yesterday with large trades towards the end of the session, however these were mostly sells.

Still selling down a bit today, however the individual trades are all small retail volumes. Will be interesting to see if there are any larger institutional buys later in the session as happened on Friday

About double the usual volume on Nasdaq on Friday. After an initial sell off in the morning most of the afternoon trades were positive with a few large buys propping up the sp. Somewhat surprising that this stock is not trading higher in anticipation of the PDUFA date.

Another factor to consider is their current debt to equity ratio and the likelihood of near term conversion of debt to equity. I think they mentioned this possibility at the last conference call. Filsuvez approval would probably be the trigger for some dilution to reduce debt.

Any guesses as to the value of Filsuvez (if approved) to the AMYT share price? If they get a voucher that should be worth about 10%. Initial sales volumes for the first few quarters will probably be good as patients try it out for effectiveness. I guess this could be worth 20-30% - so maybe 30-40% upside to the current SP ?

Maybe they should snap up ORPH while it's still cheap.
Currently around £170million market cap - down a lot from March/April highs

Someone seems to willing to pay $12.45 pre-market on NASDAQ

SVB Leerink and Cowen have both initiated coverage of AMYT with $22 target

The last few paragraphs list some recent transactions in AMYT by various institutional investors:
https://www.americanbankingnews.com/2021/08/09/amryt-pharma-nasdaqamyt-earns-buy-rating-from-hc-wainwright.html

Good to hear the recent meeting with the FDA did not raise any issues - so it looks like the Filsuvez priority review is still on track

https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+H.C.+Wainwright+Starts+Amryt+%28AMYT%29+at+Buy/18723140.html

The details of the Davy deal including the expected price and the separate disposal of the fund unit were widely covered in the media over the last few weeks - the announcement was always expected this week .

It's always a good sanity check to compare movements in BIRG with the Euro STOXX Banks ETF (EXX1.DE)
This gives an indication if any price movements are general or specific to BIRG - recently BIRG is just tracking
EXX1 i.e. general weakness in the banks - nothing BIRG specific.

Interesting RNS - it looks like up until last Friday the market was not sure about the merger - hence the wrong price ratio between CHMA and AMYT. I guess the market got some inkling on Friday to believe it will happen, resulting in huge volumes on CHMA as the price adjusted to more closely reflect the correct ratio. Maybe AMYT is just rising based on more certainty about the buyout?

Huge volume on CHMA yesterday - over 20% of the market cap. CHMA had been significantly undervalued based on the .396 conversion rate to AMYT. However, that doesn't account for the corresponding rise in AMYT. Something else going on here.

CHMA and AMYT both moving now - some big trades on CHMA.

It's really down to the perception of future profitability. Rightly or wrongly the market cap for Krystal
is based on the markets belief that their gene therapy/delivery systems have the potential to be highly
effective - also that they could be leveraged for multiple different skin related indications.